68Ga-NODAGA-JR11与68Ga-DOTATATE PET/CT在转移性高分化神经内分泌肿瘤患者中的头对头比较:一项前瞻性双中心研究的中期分析
这项前瞻性双中心研究纳入48例组织学证实、转移性或不可切除的高分化神经内分泌肿瘤患者,每例先后接受68Ga-DOTATATE和68Ga-NODAGA-JR11全身PET/CT。结果显示68Ga-NODAGA-JR11正常器官本底摄取更低,检出肝脏病灶更多(673 vs 584,P=0.002),肝病灶靶本比更高(6.4±8.7 vs 3.1±2.6,P=0.000),敏感性分别为91.7%和77.2%;14.5%(7/48)患者中68Ga-NODAGA-JR11 PET可能对临床管理有潜在影响。
要点
- 68Ga-NODAGA-JR11正常器官本底摄取低于68Ga-DOTATATE。
- 68Ga-NODAGA-JR11检出肝脏病灶数多于68Ga-DOTATATE(673 vs 584,P=0.002)。
- 68Ga-NODAGA-JR11肝病灶靶本比高于68Ga-DOTATATE(6.4±8.7 vs 3.1±2.6,P=0.000)。
核心结论
- 68Ga-NODAGA-JR11较68Ga-DOTATATE显示更好的敏感性和更高的靶本比。
- 拮抗剂检出更多病灶可能对亚组患者的临床管理有潜在影响。
研究设计与样本
- 前瞻性双中心研究,计划纳入100例组织学证实、转移性或不可切除的高分化神经内分泌肿瘤患者,首批48例构成研究队列。
- 每例患者第1天接受68Ga-DOTATATE、第2天接受68Ga-NODAGA-JR11,注射后40-60分钟行全身PET/CT。
- 比较正常器官摄取、病灶数量、病灶摄取和敏感性,并评估对临床管理的潜在影响。
主要发现
- 68Ga-NODAGA-JR11正常器官本底摄取更低。
- 68Ga-NODAGA-JR11检出肝脏病灶673个 vs 68Ga-DOTATATE 584个(P=0.002)。
- 肝病灶靶本比68Ga-NODAGA-JR11为6.4±8.7 vs 68Ga-DOTATATE为3.1±2.6(P=0.000)。
- 原发灶、骨病灶和淋巴结转移灶摄取两者相当。
- 15例患者常规影像检出180个病灶,68Ga-NODAGA-JR11阳性165个、68Ga-DOTATATE阳性139个,敏感性分别为91.7%和77.2%。
关键数值与推荐
- 肝脏病灶检出数:68Ga-NODAGA-JR11 673个 vs 68Ga-DOTATATE 584个(P=0.002)。
- 肝病灶靶本比:68Ga-NODAGA-JR11 6.4±8.7 vs 68Ga-DOTATATE 3.1±2.6(P=0.000)。
- 以常规影像180个病灶为参照,敏感性:68Ga-NODAGA-JR11 91.7% vs 68Ga-DOTATATE 77.2%。
- 可能影响临床管理的患者比例:14.5%(7/48)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current study aimed to compare 68Ga-NODAGA-Cpa-cyclo(d-Cys-amino-Phe-hydroorotic acid-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. Methods: A prospective bicenter study aimed at enrolling 100 patients with histologically proven, metastatic or unresectable, well-differentiated neuroendocrine tumors was conducted. The first 48 patients represented the study cohort. Each patient received 68Ga-DOTATATE on the first day and 68Ga-NODAGA-JR11 on the second day. Whole-body PET/CT scans were performed at 40-60 min after injection. Normal-organ uptake, lesion numbers, lesion uptake, and sensitivity were compared. The potential impact on clinical management was also determined. Results: Overall, 68Ga-NODAGA-JR11 demonstrated lower background uptake in normal organs. Compared with 68Ga-DOTATATE, 68Ga-NODAGA-JR11 detected significantly more liver lesions (673 vs. 584, P = 0.002). The target-to-background ratio of liver lesions was significantly higher on 68Ga-NODAGA-JR11 (6.4 ± 8.7 vs. 3.1 ±2.6, P = 0.000). Comparable uptake was observed for primary tumors, bone lesions, and lymph node metastases. In total, 180 lesions were detected on conventional imaging in 15 patients; 165 and 139 lesions of them were positive on 68Ga-NODAGA-JR11 and 68Ga-DOTATATE, leading to a sensitivity of 91.7% and 77.2%, respectively. In 14.5% (7/48) of patients, 68Ga-NODAGA-JR11 PET might have a potential impact on clinical management. Conclusion: 68Ga-NODAGA-JR11 shows better sensitivity and a higher target-to-background ratio than 68Ga-DOTATATE. The detection of more lesions by the antagonist may have a potential impact on clinical management in a subgroup of patients.
引用
- Lin Z, Zhu W, Zhang J, et al. Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study. J Nucl Med. 2023. PMID: 37474267. doi:10.2967/jnumed.122.264890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。